Developer docs
API playgroundTry for free, no card

Search company profiles

iDEL Therapeutics

Full company profile

uuid022qoo5

Namestring
iDEL Therapeutics
Legal namestring
iDEL Therapeutics GmbH
Websiteurl
idel-tx.com
Company typeenum
Private
Founded yearint
2025
Descriptiontext

iDEL's current pipeline consists of two lead programs being advanced toward clinical evaluation: Lead Candidate #1, a single-domain antibody for intracellular oncogene targeting, and Lead Candidate #2, a Multicancer Drug Conjugate (MDC). The company is pre-revenue, with no commercial products, and its disclosed revenue model anticipates value creation through strategic partnerships and future licensing/royalties once candidates progress clinically. It publicly launched in March 2026 with a €9 million seed financing led by BiomedVC (with NRW.Venture, Gründerfonds Ruhr, and KHAN Technology Transfer Fund II) and is led by an experienced founding team and board, including a Chair with a prior €1 billion-plus pharma exit (Cardior/Novo Nordisk). The company is positioning itself for outbound business development, including a scheduled presentation at Bio€quity Europe in May 2026.

Short descriptiontext

iDEL Therapeutics is a Dortmund-based, pre-clinical biotech developing a synthetic shuttle platform that delivers therapeutics directly into the cytosol of solid tumor cells to bypass endosomal trapping and access intracellular cancer targets.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersDortmund, Germany
HQ citystring
Dortmund
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cancer therapeutics, drug delivery platform, intracellular targeting, oncology pipeline, synthetic shuttle technology
Industry2 codes
PRIMARYHLAAAAAJ
Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Oncology Pharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pipeline Development and Clinical Advancement
TypeLicensing Royalties
Description

As a pre-revenue biotech company founded in 2025, iDEL Therapeutics is focused on advancing its oncology pipeline toward clinical evaluation. The company plans to create scalable value through strategic partnerships. Revenue generation will depend on successful clinical development, regulatory approval, and commercialization of its cancer therapeutics.

idel-tx.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

iDEL Therapeutics develops a proprietary synthetic shuttle platform that delivers therapeutic payloads directly into the cytosol of tumor cells, bypassing endosomal entrapment and unlocking previously undruggable intracellular cancer targets. The company is advancing two preclinical lead candidates — a single-domain antibody for intracellular oncogene targeting (Lead Candidate #1) and a Multicancer Drug Conjugate (MDC, Lead Candidate #2) — and intends to create value through clinical advancement and strategic partnerships.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

iDEL Therapeutics is developing a pipeline of cancer therapeutics based on its proprietary synthetic shuttle platform for direct cytosolic drug delivery. The platform consists of two lead programs: Lead Candidate #1 (a single-domain antibody targeting intracellular oncogenes) and Lead Candidate #2 (a multicancer drug conjugate). The technology enables delivery of both large and small molecules directly into tumor cell cytosol, bypassing endosomal trapping that limits conventional therapies.

Product and service3 records
1iDEL Synthetic Shuttle Platform
CategoryDrug Delivery Platform / Oncology
Description

A modular, synthetic shuttle system that transports therapeutic payloads directly into the cytosol of tumor cells, bypassing endosomal trapping and enabling access to previously undruggable intracellular targets for treating solid tumors. Designed as a plug-and-play platform for out-licensing and strategic partnerships.

2Lead Candidate #1 (Single-domain antibody for intracellular oncogen targeting)
CategoryOncology Biologic / Therapeutic Candidate
Description

A single-domain antibody therapeutic designed for direct cytosolic delivery via the iDEL shuttle platform to target intracellular oncogenes in solid tumors; currently in preclinical development.

3Lead Candidate #2 (MDC - Multicancer Drug Conjugate)
CategoryOncology Biologic / Therapeutic Candidate
Description

A multicancer drug conjugate (MDC) built on the synthetic shuttle platform, designed for targeted cancer therapy across multiple tumor types; currently in preclinical development.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierExploratoryTypeStrategic or Co-development Partner
Description

Company is actively seeking strategic partnerships to jointly expand therapeutic possibilities and increase patient benefit across cancer indications. The versatile plug-and-play platform enables delivery of a wide spectrum of payloads from small molecules to large molecules.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Molecular Partners develops DARPin-based therapeutics, an engineered protein scaffold platform for oncology and ophthalmology. Its modular, engineered-protein approach to targeted therapeutics is highly comparable to iDEL's synthetic shuttle protein engineering strategy.

TypeDirect peer
Description

Heidelberg Pharma develops antibody-targeted Amanitin conjugates (ATACs) and ADC platforms with proprietary linker chemistry. Comparable to iDEL because it is also a platform-based targeted cancer payload delivery company addressing solid tumors with novel chemistry.

TypeEmerging player
Description

Abalos Therapeutics develops engineered viruses to induce anti-tumor immune responses in solid tumors. Directly relevant because iDEL's CEO Dr. Marcus Kostka was previously CEO of Abalos (2019-2024), making it a comparable European preclinical/early-clinical oncology platform.

TypeEmerging player
Description

Tessellate Bio (now Elasmogen) develops next-generation cancer therapies, and is directly relevant because iDEL's CSO Dr. Jürgen Moll was previously CSO at Tessellate Bio and led a €500M+ deal with Boehringer Ingelheim. Comparable novel oncology modality focus.

TypeEmerging player
Description

MODAG develops targeted therapies for neurodegenerative diseases and was co-founded by iDEL's CEO Marcus Kostka. Comparable as a small European biotech emerging from academic research with a novel small-molecule mechanism in an area of high unmet need.

TypeEmerging player
Description

Araris Biotech develops site-specific ADCs using its proprietary linker technology for oncology. Comparable as a European ADC platform peer aiming to improve intracellular payload delivery to tumor cells, though focused on ADC format rather than broad shuttle delivery.

TypeDirect peer
Description

Tubulis builds next-generation ADCs with proprietary payload and linker chemistries to improve therapeutic index in solid tumors. Comparable as a European biotech developing modular targeted delivery platforms for cancer therapeutics, similar stage and funding profile.

TypeDirect peer
Description

Bicycle Therapeutics develops bicyclic peptides (Bicycles) engineered to penetrate cells and bind intracellular protein targets, addressing the same undruggable intracellular space as iDEL's shuttle platform. It is the most analogous peer in cytosolic delivery of therapeutic payloads to solid tumors.

TypeEmerging player
Description

BioAtla develops Conditionally Active Biologics (CABs) that target tumor-specific microenvironments with engineered antibodies and ADCs. Comparable in its protein-engineering approach to selectively engage solid tumors and deliver cytotoxic payloads intracellularly.

TypeEmerging player
Description

Cardior Pharmaceuticals developed RNA-based therapeutics for heart disease and was acquired by Novo Nordisk for over €1B. Relevant as iDEL's Board Chair Dr. Claudia Ulbrich led Cardior to that exit, providing a comparable European biotech exit narrative.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

iDEL Therapeutics

Oncology Pharmaceuticalsidel-tx.com

iDEL Therapeutics is a Dortmund-based, pre-clinical biotech developing a synthetic shuttle platform that delivers therapeutics directly into the cytosol of solid tumor cells to bypass endosomal trapping and access intracellular cancer targets.

What iDEL Therapeutics does

iDEL's current pipeline consists of two lead programs being advanced toward clinical evaluation: Lead Candidate #1, a single-domain antibody for intracellular oncogene targeting, and Lead Candidate #2, a Multicancer Drug Conjugate (MDC). The company is pre-revenue, with no commercial products, and its disclosed revenue model anticipates value creation through strategic partnerships and future licensing/royalties once candidates progress clinically. It publicly launched in March 2026 with a €9 million seed financing led by BiomedVC (with NRW.Venture, Gründerfonds Ruhr, and KHAN Technology Transfer Fund II) and is led by an experienced founding team and board, including a Chair with a prior €1 billion-plus pharma exit (Cardior/Novo Nordisk). The company is positioning itself for outbound business development, including a scheduled presentation at Bio€quity Europe in May 2026.

iDEL Therapeutics firmographics

Firmographics
Name
iDEL Therapeutics
Legal name
iDEL Therapeutics GmbH
Website
https://idel-tx.com
Company type
Private
Founded year
2025
Operating status
Operating
Headcount range
1–10 employees
Short description
iDEL Therapeutics is a Dortmund-based, pre-clinical biotech developing a synthetic shuttle platform that delivers therapeutics directly into the cytosol of solid tumor cells to bypass endosomal trapping and access intracellular cancer targets.
Ownership category
akta.pro rank

iDEL Therapeutics industry classification

Industry
Product category
Oncology Pharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAAAJ
Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Cancer therapeutics
  • Drug delivery platform
  • Intracellular targeting
  • Oncology pipeline
  • Synthetic shuttle technology

Where iDEL Therapeutics is headquartered

Location

Headquarters

HQ city
Dortmund
HQ country
Germany
HQ region
Europe

Offices1 record

Markets served

iDEL Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Pipeline Development and Clinical Advancement: As a pre-revenue biotech company founded in 2025, iDEL Therapeutics is focused on advancing its oncology pipeline toward clinical evaluation. The company plans to create scalable value through strategic partnerships. Revenue generation will depend on successful clinical development, regulatory approval, and commercialization of its cancer therapeutics.

Go-to-market motion1 record

Marketing channels5 records

iDEL Therapeutics product offering

Product offering

Core offering

iDEL Therapeutics develops a proprietary synthetic shuttle platform that delivers therapeutic payloads directly into the cytosol of tumor cells, bypassing endosomal entrapment and unlocking previously undruggable intracellular cancer targets. The company is advancing two preclinical lead candidates — a single-domain antibody for intracellular oncogene targeting (Lead Candidate #1) and a Multicancer Drug Conjugate (MDC, Lead Candidate #2) — and intends to create value through clinical advancement and strategic partnerships.

Product overview

iDEL Therapeutics is developing a pipeline of cancer therapeutics based on its proprietary synthetic shuttle platform for direct cytosolic drug delivery. The platform consists of two lead programs: Lead Candidate #1 (a single-domain antibody targeting intracellular oncogenes) and Lead Candidate #2 (a multicancer drug conjugate). The technology enables delivery of both large and small molecules directly into tumor cell cytosol, bypassing endosomal trapping that limits conventional therapies.

Differentiator

Problem solved

Functional benefit

Products and services

  • iDEL Synthetic Shuttle Platform A modular, synthetic shuttle system that transports therapeutic payloads directly into the cytosol of tumor cells, bypassing endosomal trapping and enabling access to previously undruggable intracellular targets for treating solid tumors. Designed as a plug-and-play platform for out-licensing and strategic partnerships.
  • Lead Candidate #1 (Single-domain antibody for intracellular oncogen targeting) A single-domain antibody therapeutic designed for direct cytosolic delivery via the iDEL shuttle platform to target intracellular oncogenes in solid tumors; currently in preclinical development.
  • Lead Candidate #2 (MDC - Multicancer Drug Conjugate) A multicancer drug conjugate (MDC) built on the synthetic shuttle platform, designed for targeted cancer therapy across multiple tumor types; currently in preclinical development.

Companies that use iDEL Therapeutics

Customer profile

Segments1 record

Ideal customer profiles1 record

iDEL Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

iDEL Therapeutics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Strategic Partnership CandidatesexploratoryStrategic or Co-development PartnerCompany is actively seeking strategic partnerships to jointly expand therapeutic possibilities and increase patient benefit across cancer indications. The versatile plug-and-play platform enables delivery of a wide spectrum of payloads from small molecules to large molecules.

Scale indicators2 records

Recent moves6 records

Expansion highlights6 records

iDEL Therapeutics competitors and assessment

Company assessment

Direct peers

  • Molecular Partners: Molecular Partners develops DARPin-based therapeutics, an engineered protein scaffold platform for oncology and ophthalmology. Its modular, engineered-protein approach to targeted therapeutics is highly comparable to iDEL's synthetic shuttle protein engineering strategy.
  • Heidelberg Pharma: Heidelberg Pharma develops antibody-targeted Amanitin conjugates (ATACs) and ADC platforms with proprietary linker chemistry. Comparable to iDEL because it is also a platform-based targeted cancer payload delivery company addressing solid tumors with novel chemistry.
  • Tubulis: Tubulis builds next-generation ADCs with proprietary payload and linker chemistries to improve therapeutic index in solid tumors. Comparable as a European biotech developing modular targeted delivery platforms for cancer therapeutics, similar stage and funding profile.
  • Bicycle Therapeutics: Bicycle Therapeutics develops bicyclic peptides (Bicycles) engineered to penetrate cells and bind intracellular protein targets, addressing the same undruggable intracellular space as iDEL's shuttle platform. It is the most analogous peer in cytosolic delivery of therapeutic payloads to solid tumors.

Emerging players

  • Abalos Therapeutics: Abalos Therapeutics develops engineered viruses to induce anti-tumor immune responses in solid tumors. Directly relevant because iDEL's CEO Dr. Marcus Kostka was previously CEO of Abalos (2019-2024), making it a comparable European preclinical/early-clinical oncology platform.
  • Tessellate Bio: Tessellate Bio (now Elasmogen) develops next-generation cancer therapies, and is directly relevant because iDEL's CSO Dr. Jürgen Moll was previously CSO at Tessellate Bio and led a €500M+ deal with Boehringer Ingelheim. Comparable novel oncology modality focus.
  • MODAG GmbH: MODAG develops targeted therapies for neurodegenerative diseases and was co-founded by iDEL's CEO Marcus Kostka. Comparable as a small European biotech emerging from academic research with a novel small-molecule mechanism in an area of high unmet need.
  • Araris Biotech: Araris Biotech develops site-specific ADCs using its proprietary linker technology for oncology. Comparable as a European ADC platform peer aiming to improve intracellular payload delivery to tumor cells, though focused on ADC format rather than broad shuttle delivery.
  • BioAtla: BioAtla develops Conditionally Active Biologics (CABs) that target tumor-specific microenvironments with engineered antibodies and ADCs. Comparable in its protein-engineering approach to selectively engage solid tumors and deliver cytotoxic payloads intracellularly.
  • Cardior Pharmaceuticals: Cardior Pharmaceuticals developed RNA-based therapeutics for heart disease and was acquired by Novo Nordisk for over €1B. Relevant as iDEL's Board Chair Dr. Claudia Ulbrich led Cardior to that exit, providing a comparable European biotech exit narrative.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

iDEL Therapeutics social profiles

Digital presence

iDEL Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

iDEL Therapeutics leadership team

Management profile

Number of profiles

Profiles5 records

iDEL Therapeutics funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

iDEL Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about iDEL Therapeutics

What does iDEL Therapeutics do?

iDEL Therapeutics develops a proprietary synthetic shuttle platform that delivers therapeutic payloads directly into the cytosol of tumor cells, bypassing endosomal entrapment and unlocking previously undruggable intracellular cancer targets. The company is advancing two preclinical lead candidates — a single-domain antibody for intracellular oncogene targeting (Lead Candidate #1) and a Multicancer Drug Conjugate (MDC, Lead Candidate #2) — and intends to create value through clinical advancement and strategic partnerships.

Is iDEL Therapeutics a public or private company?

iDEL Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was iDEL Therapeutics founded?

iDEL Therapeutics was founded in 2025. It employs 1 to 10 people.

Where is iDEL Therapeutics based?

iDEL Therapeutics is headquartered in Dortmund, Germany, in the Europe region.

How does iDEL Therapeutics make money?

One revenue line is on record: pipeline Development and Clinical Advancement.

Who are iDEL Therapeutics's main competitors?

Direct peers on record are Molecular Partners, Heidelberg Pharma, Tubulis and Bicycle Therapeutics. Emerging players are Abalos Therapeutics, Tessellate Bio, MODAG GmbH, Araris Biotech, BioAtla and Cardior Pharmaceuticals.

Does iDEL Therapeutics have an API?

No public API is recorded for iDEL Therapeutics.

What industry is iDEL Therapeutics in?

iDEL Therapeutics's product category is Oncology Pharmaceuticals. Its primary akta.pro industry code is HLAAAAAJ, Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds), with a secondary code of HLAAAIAC, Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business & FinancialIdel Therapeutics Enters Global Research Collaboration With Daiichi Sankyo To Develop Multi-Drug Conjugate With Targeted Cytosolic Delivery Into Solid Tumor CellsiDEL Therapeutics announced a research collaboration with Daiichi Sankyo to evaluate a multi-drug conjugate for solid tumors using its synthetic shuttle platform. The preclinical study will compare the MDC to an antibody-drug conjugate with a comparable payload. Further details were not disclosed.YahooiDEL Therapeutics Enters Global Research Collaboration with Daiichi Sankyo to Develop Multi-Drug Conjugate with Targeted Cytosolic Delivery into Solid Tumor CellsiDEL Therapeutics announced a research collaboration with Daiichi Sankyo to evaluate a multi-drug conjugate for solid tumors using its synthetic shuttle platform. The preclinical study will compare the MDC to an antibody-drug conjugate with a comparable payload. Further details of the agreement were not disclosed.GlobeNewswireiDEL Therapeutics Enters Global Research Collaboration with Daiichi Sankyo to Develop Multi-Drug Conjugate with Targeted Cytosolic Delivery into Solid Tumor CellsiDEL Therapeutics announced a research collaboration with Daiichi Sankyo to evaluate a multi-drug conjugate for solid tumors using its synthetic shuttle platform. The preclinical study will compare the MDC to an antibody-drug conjugate with a comparable payload. Further details were not disclosed.GlobeNewswireiDEL Therapeutics Appoints Claudia Ulbrich as Chair of its Board of DirectorsiDEL Therapeutics appointed Claudia Ulbrich, MD, as Chair of its Board of Directors. She brings over 25 years of biotech leadership, including CEO of Cardior Pharmaceuticals, which was acquired by Novo Nordisk for over EUR 1 billion in 2024. The company will leverage her expertise to advance its pan-cancer drug pipeline.StartupmafiaGerman BioTech iDEL Therapeutics Lands €9 Million to Develop Cancer Therapeutics PlatformDortmund-based iDEL Therapeutics has closed a €9 million Seed financing round led by BiomedVC, with participation from NRW.Venture, Gründerfonds Ruhr, and KHAN Technology Transfer Fund II, to advance its pipeline of cancer therapeutics delivered directly into tumor cell cytosol. Founded in 2025, the company leverages a synthetic shuttle technology that evades endosomal trapping to unlock intracellular drug delivery for solid tumors. The funding will advance two proprietary lead programs toward clinical evaluation, with the round situated within broader European biotech oncology investment activity totaling approximately €83.8 million.BioSpaceiDEL Therapeutics Appoints Claudia Ulbrich as Chair of its Board of DirectorsiDEL Therapeutics appointed Claudia Ulbrich, MD, a seasoned biotech executive with a track record including the EUR 1 billion acquisition of Cardior Pharmaceuticals by Novo Nordisk in 2024, as Chair of its Board of Directors. The appointment aims to leverage her expertise in executive management, business development, and R&D oversight as the company advances its pan-cancer drug delivery platform toward clinical development.StartbaseNRW.BANK invests in iDEL TherapeuticsNRW.BANK has invested EUR 3.5 million in iDEL Therapeutics through its venture capital fund NRW.Venture as part of a seed financing round totaling EUR 9 million. The round was led by BioMedVC with participation from Gründerfonds Ruhr and KHAN Technology Transfer Fund II. The funding will support iDEL Therapeutics' development of a targeted drug delivery technology designed to transport active substances directly into cancer cells while sparing healthy cells, with the goal of improving treatment effectiveness and reducing side effects.Pulse 2.0iDEL Therapeutics: €9 Million Raised To Advance Cytosolic Cancer Drug Delivery PlatformiDEL Therapeutics, a German biotech company based in Dortmund, has raised €9 million in seed financing to advance its cytosolic drug delivery platform for cancer treatment. The funding round was led by BiomedVC with participation from NRW.Venture, Gründerfonds Ruhr, and KHAN Technology Transfer Fund II. The company plans to use the capital to establish operations, build its leadership team, and advance two lead programs toward clinical evaluation, with the platform designed to bypass endosomal trapping and enable direct delivery of therapeutics into tumor cell cytosol.BioSpaceR1 Leads Busy Fundraising Day With $77.5M Series A Raise for Kidney DiseaseR1 Therapeutics, a California-based biotech startup, raised $77.5 million in an oversubscribed Series A round co-led by Abingworth, F-Prime, and DaVita Venture Group to advance AP306, a novel pan phosphate transporter inhibitor for treating hyperphosphatemia in chronic kidney disease patients. The drug was originally developed by Chugai and licensed to R1 through China's Alebund Pharmaceuticals, which retains rights in Greater China; Phase 2a data showed approximately 20% better efficacy compared to Sanofi's Renvela. Two other biotech companies also completed fundraising on the same day, with Mestag Therapeutics securing $40 million for its solid tumor bispecific antibody program and iDEL Therapeutics raising €9 million for its cytosol-delivery cancer drug technology.